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Abstract
Background: Phase Three of the International Study of Asthma and Allergies in
Childhood (ISAAC) measured the global prevalence of symptoms of asthma in chil-
dren. We undertook comprehensive analyses addressing risk factors for asthma
symptoms in combination, at both the individual and the school level, to explore the
potential role of reverse causation due to selective avoidance or confounding by
indication.
Objective: To explore the role of reverse causation in risk factors of asthma
symptoms.
Methods: We compared two sets of multilevel logistic regression analyses, using (a)
individual level exposure data and (b) school level average exposure (ie prevalence),
in two different age groups. In individual level analyses, reverse causation is a possi-
ble concern if individual level exposure statuses were changed as a result of asthma
symptoms or diagnosis. School level analyses may suffer from ecologic confounding,
but reverse causation is less of a concern because individual changes in exposure
status as a result of asthma symptoms would only have a small effect on overall
school exposure levels.
Results: There were 131 924 children aged 6‐7 years (2428 schools, 25 countries)
with complete exposure, outcome and confounder data. The strongest associations
in individual level analyses (fully adjusted) were for current paracetamol use (odds
ratio = 2.06; 95% confidence interval 1.97‐2.16), early life antibiotic use (1.65; 1.58‐
1.73) and open fire cooking (1.44; 1.26‐1.65). In school level analyses, these risk fac-
tors again showed increased risks.
There were 238 586 adolescents aged 13‐14 years (2072 schools, 42 countries)
with complete exposure, outcome and confounder data. The strongest associations
in individual level analyses (fully adjusted) were for current paracetamol use (1.80;
aISAAC Phase Three Study group listed at end of paper are listed in Appendix.
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1.75‐1.86), cooking on an open fire (1.32; 1.22‐1.43) and maternal tobacco use
(1.23; 1.18‐1.27). In school level analyses, these risk factors again showed increased
risks.
Conclusions & clinical relevance: These analyses strengthen the potentially causal
interpretation of previously reported individual level findings, by providing evidence
against reverse causation.
K E YWORD S
asthma, environment and hygiene hypothesis, epidemiology
1 | INTRODUCTION
Asthma is becoming increasingly important as a childhood disease on
a global basis.1 The Global Asthma Report 2018 estimated that as
many as 339 million people have asthma and that the burden of dis-
ability is high.2
The International Study of Asthma and Allergies in Childhood
(ISAAC), using a simple and inexpensive standardized methodology,3-5
has documented a wide variation of asthma prevalence in different
parts of the world,6,7 and a number of papers have been published
addressing the findings for individual risk factors, with several associa-
tions observed (see “Variables” below).8-20 However, these risk factors
have not previously been considered together within the same analy-
sis, so it is possible that some of the observed associations may be at
least partially due to confounding by other risk factors.
The current paper represents the first comprehensive analyses to
address these risk factors together, in order to fill this gap in the
current knowledge. We have done this in two ways. Firstly, we have
conducted a “standard” analysis using the individual level exposure
data for each risk factor (eg maternal smoking). However, for some
risk factors the cross‐sectional nature of the study means that such
analyses may be subject to “reverse causation” if individual level
exposure statuses were changed as a result of asthma symptoms or
diagnosis. This may occur due to selective avoidance (eg if the child's
mother stops smoking because the child has developed asthma) or
“confounding by indication” (eg if exposures such as paracetamol or
antibiotics are taken in response to symptoms which are related to
the subsequent development of asthma).
As schools were the level of sampling in ISAAC, we have there-
fore conducted a second set of analyses using the school level aver-
age reported exposure (ie the prevalence; rather than the reported
individual exposure) to each risk factor to attempt to avoid or mini-
mize such biases. School level analyses may suffer from ecologic
(community‐level) confounding, but reverse causation is perhaps less
of a concern because individual changes in exposure status as a
result of asthma symptoms would only have a small effect on overall
school exposure levels. It is therefore of considerable interest to
compare the individual level and school level analyses.
If reverse causation due to confounding by indication was exerting
a major influence on the individual level associations, we would expect
the associations to be much reduced at the school level. Conversely, if
there was reverse causation due to selective avoidance, we would
expect a stronger association at the school level, although this could
also be due to contextual factors operating at the school level. Consis-
tency of findings at the two levels thus provides indirect evidence
against reverse causation and against strong contextual factors.
Biases may differ in different parts of the world, for example
breastfeeding is more strongly associated with socio‐economic status
in high‐income countries than in low‐ and middle‐income countries,21
hence there is a greater potential for confounding by socio‐economic
status in the former. Therefore we additionally conducted analyses
stratified by country‐level affluence to examine the extent to which
associations and biases differed.
2 | METHODS
2.1 | Study
ISAAC Phase Three methods have been described in detail else-
where4 and will be summarized briefly here. ISAAC Phase Three is a
multi‐centre, multi‐country, cross‐sectional study of two age groups
of schoolchildren (6‐7‐year‐old children and 13‐14‐year‐old adoles-
cents) chosen from a random sample of schools in a defined geo-
graphical area.3,4 The Phase Three survey took place in 2000‐2003
and included two standardized questionnaires. The first obtained
data on symptoms of asthma, rhinoconjunctivitis and eczema and
was identical to that used in Phase One of ISAAC.6,22 The second,
the environmental questionnaire, obtained data on a range of
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possible risk factors for the development of asthma and allergic dis-
orders.8 The questionnaires can be found on the ISAAC website
(http://isaac.auckland.ac.nz).
2.2 | Variables
We considered the outcome of wheeze in the last 12 months,
defined by a positive response to the question “Has your child/have
you had wheezing or whistling in the chest in the past 12 months?”
In many countries in the world, we find that most asthma (based on
symptoms) has not been diagnosed, which is why ISAAC is based on
symptoms. The ISAAC symptoms questionnaire validates well against
doctor‐diagnosed asthma.23
The environmental questionnaires in the two age groups did
not contain identical questions, so it was not possible to examine
the same set of potential risk factors in each age group. In addi-
tion, we restricted our analyses to the risk factors which had
shown associations with wheeze in the last 12 months in previous
analyses at the individual level. For the younger age group, we
included paracetamol use in the first year of life and in the past
12 months,8 antibiotic use in the first year of life,20 breastfeeding,9
cat in the home in the first year of life,11 regular contact with farm
animals in the first year of life,12 truck traffic,10 fast food consump-
tion,13 television viewing,15 parental smoking,16 cooking on an open
fire19 and birth weight.17 For the older age group, we included
truck traffic,10 fast food consumption,13 television viewing,15 paren-
tal smoking,16 paracetamol use in the past 12 months24 and open
fire cooking.19
Most of the above risk factors were parameterised as binary
variables from “yes/no” questions in the environmental questionnaire.
The exceptions were as follows: paracetamol use in the past
12 months (at least once per month vs less than once per month),
truck traffic (seldom or more frequently vs never), fast food con-
sumption (once per week or more vs less than once per week), tele-
vision viewing (at least 1 hour per day vs less than 1 hour per day)
and birth weight (less than 2.5 kg vs at least 2.5 kg). Full definitions
are in Table S1.
Sex was self‐reported as male/female, and the highest level of
maternal education was recorded as primary, secondary, tertiary or
missing/not stated.
Gross National Income (GNI) as of 2002 was obtained from the
World Bank website25 where available, with gaps filled by the CIA
World Factbook.26 Countries were classified as “affluent” or “non‐
affluent” using a 2001 GNI value of US$9205 per capita as a cut‐off,
which separates high‐income countries from low‐ and middle‐income
countries.27
2.3 | Statistical analyses
To be included in the analysis for a particular age group, centres had
to include at least 1000 individuals and to have a response rate of
>60% for children and >70% for adolescents. Analyses were con-
ducted separately in the two age groups. Within each age group,
schools with fewer than 10 individuals were excluded from the
analysis.
All analyses were conducted using mixed effect (multilevel) logis-
tic regression models. The four‐level hierarchical nature of the data
(individuals [level 1], schools [level 2], centres [level 3] and countries
[level 4]) was acknowledged by allowing random intercepts at levels
2, 3 and 4 in individual level models and by including random inter-
cepts at levels 3 and 4 in school level models. Centres were self‐
selected, whereas schools were randomly sampled within centres,
making school the preferred level of analysis. Sex and maternal
education were adjusted for as individual level confounders in all
models.
Three different modelling approaches were used: (a) individual
level, (b) school level and (c) hybrid fixed effects.28 However, results
from the hybrid fixed effect models were very similar to those from
the individual level and school level models, so they are not dis-
cussed further.
Individual level models related the individual level outcome to
each individual level risk factor within schools. School level models
related the individual level outcome to the school level average
exposure (ie prevalence) of each risk factor. In these models, the
estimated OR corresponding to the school level prevalence of the
risk factor can be interpreted as the effect on the individual outcome
of attending a school where all children are exposed compared to
attending a school where no one is exposed.
Within each approach, models were fitted for: (a) each exposure
of interest using the sub‐sample who had data present for wheeze,
sex, maternal education and the given exposure (the “maximum sam-
ple”), (b) each exposure of interest using the sub‐sample who had
data present for wheeze, sex, maternal education and all exposures
of interest (the “common sample”) and (c) each exposure of interest
mutually adjusted using the sub‐sample who had data present for
wheeze, sex, maternal education and all exposures of interest (the
“common sample”).
The extent of collinearity in the mutually adjusted models was
examined by comparing the standard errors in the mutually adjusted
model and the minimally adjusted model fitted to the same sub‐sam-
ple.29 There was no evidence of substantial collinearity.
Additionally, we ran the fully adjusted analyses separately for
“affluent” and “non‐affluent” countries. We then separately tested
for effect modification of each risk factor by country‐level affluence.
Analyses were conducted using Stata version 14.30
3 | RESULTS
3.1 | 6‐7 year olds
The 6‐7‐year‐old participants included 221 280 children from 75
centres which met the initial data quality criteria (at least 1000 chil-
dren and a response rate of >60%). Of these, 212 480 children
(from 2903 schools, 75 centres, 32 countries) were from schools
with at least 10 children and had data present for wheeze, sex,
maternal education and at least one of the exposures of interest so
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contributed to the analyses for one or more exposures (the “maxi-
mum sample”), with 131 924 children (from 2428 schools, 64 cen-
tres, 25 countries) having data present for all analysis variables (the
“common sample”). See the data flowchart (Figure 1) for further
details. Individual‐ and school level summary statistics are presented
in Table S2 for the maximum sample and in Table 1 for the common
sample.
Minimally adjusted associations in the common sample were
broadly similar to those in the maximum sample (Tables 2 and S3).
The strongest associations in the fully adjusted individual level analy-
ses were for current paracetamol use (OR = 2.06, 95% CI 1.97‐2.16),
antibiotic use in the first year of life (1.65; 1.58‐1.73) and open fire
cooking (1.44; 1.26‐1.65) (Table 2).
In the fully adjusted school level analyses, the associations for
current paracetamol use (1.58; 1.18‐2.10), early life antibiotic use
(1.38; 1.07‐1.78) and open fire cooking (2.02; 1.16‐3.50) were main-
tained (Table 2). Stronger associations were observed at the school
level compared with the individual level for low birthweight (2.13;
1.39‐3.25 compared to 1.12; 1.05‐1.21), maternal tobacco use (1.83;
1.36‐2.47 compared to 1.20; 1.14‐1.27), fast food consumption
(1.68; 1.37‐2.06 compared to 1.07; 1.03‐1.12) and early life farm ani-
mal exposure (1.36; 1.00‐1.85 compared to 1.12; 1.06‐1.20). An
association was seen at the school level only for television viewing
(1.80; 1.37‐2.37 compared to 1.04; 0.99‐1.10) (Table 2).
In the analyses stratified by country‐level affluence (Tables S4-
S5), there was strong evidence (P < 0.001) of effect modification at
the individual level for early life exposure to cats (1.36; 1.26‐1.48 in
non‐affluent countries vs 1.09; 1.00‐1.18 in affluent countries), early
life exposure to farm animals (1.23; 1.14‐1.33 vs 0.96; 0.87‐1.06)
and current paracetamol use (1.89; 1.79‐2.01 vs 2.38; 2.21‐2.56)
(Table S4).
When using the school level prevalence (Table S5), there was
again some evidence (P = 0.04) of effect modification of current
paracetamol use (1.31; 0. 89‐1.92 in non‐affluent countries vs 2.32;
1.52‐3.55 in affluent countries). However, there was little evidence
of a difference between affluent and non‐affluent countries for the
associations of wheeze with cat and farm animal exposure in the
first year of life. Several risk factors showed greater effect modifica-
tion in the school level analysis than in the individual level analysis:
maternal tobacco (3.30; 1.87‐5.83 in non‐affluent countries vs 1.49;
1.06‐2.10 in affluent countries in the school level analysis), antibi-
otics in the first year of life (1.13; 0.80‐1.61 vs 1.77; 1.22‐2.55) and
paracetamol use in the first year of life (0.90; 0.63‐1.29 vs 1.30;
0.88‐1.93).
3.2 | 13‐14 year olds
The 13‐14‐year‐old participants included 362 048 adolescents from
122 centres which met the initial data quality criteria (at least 1000
adolescents and a response rate of >70%). Of these 350 915 ado-
lescents (from 2511 schools, 122 centres, 54 countries) were from
schools with at least 10 adolescents and had data present for
wheeze, sex, maternal education and at least one of the exposures
of interest so contributed to the analyses for one or more expo-
sures (the “maximum sample”), with 238 586 adolescents (from
2072 schools, 99 centres, 42 countries) having data present for all
analysis variables (the “common sample”). See the data flowchart
(Figure 2) for further details. Individual‐ and school level summary
statistics are presented in Table S2 for the maximum sample and in
Table 1 for the common sample.
Minimally adjusted associations in the common sample were
broadly similar to those in the maximum sample (Tables 2 and S3).
The strongest associations in the fully adjusted individual level analy-
ses were for current paracetamol use (1.80; 1.75‐1.86), cooking on
an open fire (1.32; 1.22‐1.43) and maternal tobacco use (1.23; 1.18‐
1.27) (Table 2).
In the fully adjusted school level analyses, the associations for
current paracetamol use (2.31; 1.71‐3.12) and maternal tobacco use
(2.51; 1. 74‐3.61) were maintained. Although the evidence for an
association with cooking on an open fire was reduced, the point esti-
mate was comparable to that in the individual level analysis (1.28;
0.85‐1.94) (Table 2). An association was also observed at the school
level (but not the individual level) for television viewing (2.01; 1.36‐
2.96). At the individual level, there was an association with paternal
tobacco use (1.12; 1.08‐1.15), but this was in the other direction at
the school level (0.51; 0.37‐0.70).
In the analyses stratified by country‐level affluence (Tables S4-
S5), there was evidence (P < 0.001) at the individual level that
paracetamol use in the last 12 months was more strongly associated
with wheeze in affluent countries (1.97; 1.85‐2.09) than non‐affluent
(1.75; 1.69‐1.82) (Table S4). There was no evidence of effect modifi-
cation at the school level (Table S5).
4 | DISCUSSION
A number of papers have been published describing the association
of asthma symptoms with individual level risk factors in ISAAC Phase
Three.8-20 Here, we present the first comprehensive analyses to
address these risk factors together in a multilevel framework and
compare the individual level and school level findings to assess the
possibility of various types of bias and confounding.
The associations we present here at the individual level (Table 2)
generally confirm the results for recent wheeze in published ISAAC
papers. However, the ORs do not correspond exactly with previous
publications due to the following differences in analytical approach.
Firstly, the ISAAC survey methodology involved cluster sampling
(sampling schools, then selecting all children of the appropriate age
within each selected school). In previous publications, no adjustment
was made for within‐school clustering of risk factors. In our multi-
level models, inclusion of school as a random intercept adjusts more
formally for intra‐class correlation of both symptoms and exposures.
This is a strength of the multilevel modelling approach.
Secondly, previous ISAAC Phase Three publications have
adjusted for sex but not for socio‐economic status at the individual
level, whereas we included individual level maternal education as a
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socio‐economic indicator in all models. Although maternal education
is problematic to interpret as a socio‐economic indicator across
diverse study centres from different countries and cultures, it is
more likely to be valid for adjustment of socio‐economic confound-
ing within local communities, such as school catchment areas, which
is how it is used in our multilevel analyses.
Total sample
221 280 individuals
3167 schools Median 44 (range 1-1117) individuals per school
75 centres Median 3000 (range 1070-5654) individuals per centre
32 countries Median 4332 (range 1070-43 918) individuals per country
Schools with at least 10 individuals
219 853 individuals
2904 schools Median 49 (range 10-1117) individuals per school
75 centres Median 2980 (range 999-5603) individuals per centre
32 countries Median 4314 (range 1054-43 873) individuals per country
Individuals non-missing for outcome, confounders and at least one exposure 
(Maximum sample)
212 480 individuals
2903 schools Median 48 (range 8-1014) individuals per school
75 centres Median 2860 (range 895-5488) individuals per centre
32 countries Median 4244 (range 1021-42 133) individuals per country
Individuals non-missing for outcome, confounders and all exposures 
(Common sample)
131 924 individuals
2428 schools Median 36 (range 1-708) individuals per school
64 centres Median 2146 (range 192-4439) individuals per centre
25 countries Median 5043 (range 1021-42 133) individuals per country
Excluded
1427 individuals
263 schools
0 centres
0 countries
Excluded
7373 individuals
1 school
0 centres
0 countries
Excluded
80 556 individuals
475 schools
11 centres
7 countries
F IGURE 1 Data flowchart for 6‐7‐year‐old children
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Thirdly, previous ISAAC publications have adjusted for selected
confounders (with a different set for each analysis), whereas we took
a more comprehensive and harmonized approach in constructing our
fully adjusted model. Comparison between the minimally adjusted
and fully adjusted results in Table 2 confirms that the associations of
wheeze with each risk factor are mutually independent, although in
general there is some attenuation of the effects when all covariates
are included. Some factors (eg paracetamol use in the first year of
life) reduced markedly after confounder adjustment, indicating the
possibility of residual confounding due to unmeasured confounders.
Breastfeeding (in the younger children) and television viewing (in
each age group) were the only individual level risk factors which
became non‐significant after mutual adjustment, though the esti-
mated associations in the minimally adjusted models were limited in
magnitude prior to further adjustment.
A potential drawback of including multiple variables in a single
model is a reduced sample size due to missing covariate data. About
one‐third of the 6‐7‐year‐olds and about one‐quarter of the 13‐14‐
year‐olds were excluded from the fully adjusted model due to incom-
plete risk factor information. However, comparison of results from
the maximum sample with those from the common sample shows
that findings were generally very similar for the subset of respon-
dents with complete covariate data, suggesting that valid conclusions
can be drawn from the “common sample” dataset.
It should also be noted that, whilst early life exposures are less
prone to reverse causality than current exposures, recall errors
(which may be biased with respect to disease status) are perhaps
more likely to have affected early childhood exposures in an inter-
view conducted when the child was 6‐7 years old.
An innovative feature of this paper is the presentation of associ-
ations of school level prevalence of risk factors with individual level
wheeze. This type of population‐level analysis is potentially vulnera-
ble to the “ecological fallacy,”31,32 but this concept has several com-
ponents, of which only one (ecological or population‐level
confounding) applies in our study. We avoid other forms of ecologi-
cal fallacy because the population‐level exposure (school level preva-
lence of each risk factor) was derived by aggregating individual level
data, so the exposure measure relates directly to the schools actually
participating in the study (not, for instance, a city‐wide or national
average) and to the children for whom questionnaire data were
TABLE 1 Summary statistics for variables and their prevalence in subjects who had data present for wheeze, sex, maternal education and all
exposures of interest (the “common sample”)
Age group Variable
Individual level (n = 131 924)
School level (n = 2428)
Prevalence (%) Median prevalence (%) Prevalence IQR (%)
6‐7 y Wheeze in the last 12 mo 9.8 9.2 (4.7, 15.3)
Low birthweight 8.1 6.1 (2.6, 10.7)
Paracetamol (1st y) 65.4 70.6 (56.3, 83.9)
Antibiotics (1st y) 56.2 57.6 (47.1, 66.0)
Breastfed ever 81.3 85.2 (74.7, 93.7)
Cat (1st y) 11.5 9.1 (3.8, 19.0)
Farm animals (1st y) 10.2 9.1 (3.9, 16.7)
Truck traffic (current) 79.2 84.5 (75.0, 91.3)
Fast food (current) 39.9 31.6 (16.7, 50.0)
Television (current) 79.8 84.4 (73.9, 91.6)
Paternal tobacco (current) 32.3 34.4 (20.2, 48.3)
Maternal tobacco (current) 15.3 14.2 (2.1, 30.7)
Paracetamol (current) 18.3 14.7 (6.4, 28.0)
Open fire cooking (current) 2.0 0.0 (0.0, 1.7)
Age group Variable
Individual level (n = 238 586)
School level (n = 2072)
Prevalence (%) Median prevalence (%) Prevalence IQR (%)
13‐14 y Wheeze in the last 12 mo 10.6 9.8 (5.0, 15.5)
Truck traffic (current) 83.2 87.3 (79.5, 92.9)
Fast food (current) 53.6 52.8 (38.9, 67.9)
Television (current) 85.6 90.5 (81.7, 94.8)
Paternal tobacco (current) 38.3 37.3 (23.5, 49.4)
Maternal tobacco (current) 18.1 18.6 (3.4, 35.6)
Paracetamol (current) 26.7 29.4 (17.3, 41.3)
Open fire cooking (current) 5.2 0.7 (0.0, 3.0)
IQR, interquartile range.
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returned (not, for instance, children of a different age or social group
in the same area). We regard these as strengths of the multilevel
analytical approach.
The school level associations shown in Table 2 generally main-
tained their direction on mutual adjustment, but the magnitude of
the ORs (comparing the minimally adjusted and fully adjusted
results) were less stable than the corresponding individual level
associations (also in Table 2). Nevertheless, in the younger age
group, significant school level associations were observed in the
fully adjusted model with low birthweight, antibiotics in infancy,
farm animal exposure in the first year, frequent fast food and tele-
vision exposure, maternal smoking (but not paternal smoking) and
current paracetamol use (but not paracetamol use in first year of
life). In the older age group, significant school level associations
were also observed with television viewing, maternal smoking and
current paracetamol use.
The observed consistency of findings at the two levels provides
indirect evidence against reverse causation and against strong con-
textual factors. Furthermore, since the spectrum of unmeasured con-
founders is likely to be different at the individual and population
levels, consistency of results between the two levels provides addi-
tional reassurance against unmeasured confounding. Therefore, on
both counts, cross‐level consistency strengthens the evidence for a
causal relationship at the individual level.
Such cross‐level comparisons (Table 2) show a close similarity in
ORs at the individual level and school level for current paracetamol
exposure and wheeze in each age group. This is of particular interest
as a causal interpretation of this association has been disputed, due
to the possibility of reverse causation (due to confounding by indica-
tion for paracetamol use and wheezing in infancy, or due to aspirin
avoidance by older children with asthma or their families).
ISAAC Phase Three findings for paracetamol in the first year of
life have also been debated.33 At the individual level in the present
study, we found an OR of 1.75 for paracetamol use in the first year
of life, which reduced to 1.33 after adjusting for other risk factors;
this is similar to the findings from the original report,8 which had
ORs of 1.77 and 1.46 respectively. It has been suggested that this
finding may be due to either residual confounding (given that more
than one‐half of the excess risk has disappeared after adjustment for
known confounders), or due to confounding by indication.33 This
viewpoint is perhaps supported by the findings from our school level
analyses, where the minimally adjusted association with paracetamol
use in the first year of life (OR = 1.42) disappears on adjustment for
other risk factors (OR = 1.01).
TABLE 2 Effects of individual‐ and school level exposures on wheeze in the last 12 months for subjects who had data present for wheeze,
sex, maternal education and all exposures of interest (the “common sample”). Mixed logistic regression models with random intercepts at the
school, centre and country levels
Age group Exposure
Individual level exposure School level exposure
Minimally adjusteda
OR (95% CI)
Fully adjustedb
OR (95% CI)
Minimally adjusteda
OR (95% CI)
Fully adjustedb
OR (95% CI)
6‐7 y (n = 131 924) Low birthweight 1.20 (1.12, 1.29) 1.12 (1.05, 1.21) 2.43 (1.60, 3.69) 2.13 (1.39, 3.25)
Paracetamol (1st y) 1.75 (1.67, 1.84) 1.33 (1.27, 1.40) 1.42 (1.11, 1.82) 1.01 (0.78, 1.32)
Antibiotics (1st y) 1.90 (1.83, 1.98) 1.65 (1.58, 1.73) 1.49 (1.17, 1.90) 1.38 (1.07, 1.78)
Breastfed ever 0.91 (0.87, 0.96) 0.96 (0.91, 1.01) 0.80 (0.60, 1.09) 1.11 (0.82, 1.50)
Cat (1st y) 1.29 (1.22, 1.37) 1.22 (1.15, 1.29) 1.44 (1.06, 1.94) 1.20 (0.88, 1.65)
Farm animals (1st y) 1.24 (1.16, 1.31) 1.12 (1.06, 1.20) 1.47 (1.11, 1.94) 1.36 (1.00, 1.85)
Truck traffic (current) 1.24 (1.17, 1.30) 1.17 (1.11, 1.23) 1.25 (0.97, 1.62) 1.04 (0.81, 1.33)
Fast food (current) 1.14 (1.09, 1.19) 1.07 (1.03, 1.12) 1.80 (1.47, 2.20) 1.68 (1.37, 2.06)
Television (current) 1.11 (1.06, 1.17) 1.04 (0.99, 1.10) 2.08 (1.61, 2.69) 1.80 (1.37, 2.37)
Paternal tobacco (current) 1.20 (1.15, 1.25) 1.12 (1.07, 1.17) 1.51 (1.20, 1.89) 0.83 (0.63, 1.08)
Maternal tobacco (current) 1.32 (1.25, 1.38) 1.20 (1.14, 1.27) 2.22 (1.72, 2.87) 1.83 (1.36, 2.47)
Paracetamol (current) 2.35 (2.24, 2.46) 2.06 (1.97, 2.16) 2.05 (1.55, 2.71) 1.58 (1.18, 2.10)
Open fire cooking (current) 1.44 (1.26, 1.65) 1.44 (1.26, 1.65) 1.95 (1.15, 3.29) 2.02 (1.16, 3.50)
13‐14 y (n = 238 586) Truck traffic (current) 1.20 (1.15, 1.25) 1.16 (1.12, 1.21) 1.52 (1.09, 2.11) 1.28 (0.92, 1.79)
Fast food (current) 1.11 (1.08, 1.15) 1.07 (1.04, 1.10) 1.36 (1.09, 1.71) 1.21 (0.96, 1.51)
Television (current) 1.06 (1.01, 1.11) 1.02 (0.97, 1.07) 2.29 (1.56, 3.37) 2.01 (1.36, 2.96)
Paternal tobacco (current) 1.19 (1.16, 1.23) 1.12 (1.08, 1.15) 0.85 (0.63, 1.13) 0.51 (0.37, 0.70)
Maternal tobacco (current) 1.30 (1.26, 1.35) 1.23 (1.18, 1.27) 1.94 (1.39, 2.70) 2.51 (1.74, 3.61)
Paracetamol (current) 1.83 (1.78, 1.89) 1.80 (1.75, 1.86) 2.43 (1.79, 3.29) 2.31 (1.71, 3.12)
Open fire cooking (current) 1.31 (1.21, 1.41) 1.32 (1.22, 1.43) 0.98 (0.65, 1.48) 1.28 (0.85, 1.94)
aAdjusted for sex and mothers level of education.
bAdditionally adjusted for all other variables in the table.
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Another risk factor which might be prone to reverse causation
(due to pet avoidance in allergic families) is cat exposure in infancy.
Here, the school level association is somewhat stronger than the
individual level association in the minimally adjusted models, as
would be predicted from avoidance bias. However, after full adjust-
ment the estimated associations are very similar.
Total sample
362 048 individuals
2592 schools Median 100 (range 1-1169) individuals per school
122 centres Median 3022 (range 66-7384) individuals per centre
54 countries Median 3632 (range 66-46 053) individuals per country
Schools with at least 10 individuals
361 750 individuals
2528 schools Median 103 (range 10-1169) individuals per school
122 centres Median 3020 (range 66-7384) individuals per centre
54 countries Median 3632 (range 66-45 984) individuals per country
Individuals non-missing for outcome, confounders and at least one exposure
(Maximum sample)
350 915 individuals
2511 schools Median 101 (range 9-1159) individuals per school
122 centres Median 2953 (range 66-6953) individuals per centre
54 countries Median 3605 (range 66-43 238) individuals per country
Individuals non-missing for outcome, confounders and all exposures
(Common sample)
238 586 individuals
2072 schools Median 87 (range 1-976) individuals per school
99 centres Median 2587 (range 117-5869) individuals per centre
42 countries Median 4434 (range 1704-43 238) individuals per country
Excluded
298 individuals
64 schools
0 centres
0 countries
Excluded
10 835 individuals
17 schools
0 centres
0 countries
Excluded
112 329 individuals
439 schools
23 centres
12 countries
F IGURE 2 Data flowchart for 13‐14‐year‐old adolescents
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In the older age group, we found associations with paternal
tobacco smoking which differed in direction between the individual‐
and school level analyses. This was a surprising finding which we
have been unable to satisfactorily explain.
Finally, stratified analyses identified some risk factors whose
effects seemed to differ by country‐level affluence (Tables S4-S5). In
the younger age group, current paracetamol use was consistently (ie in
both individual‐ and school level analyses) found to be a stronger risk
factor for wheeze in affluent countries relative to non‐affluent coun-
tries. Cat and farm animal exposure in the first year of life were found
to be stronger risk factors in non‐affluent countries (where there is
perhaps less avoidance bias) in the individual level analysis. In the
school level analysis, the affluence level‐specific associations similarly
differed, though there was not statistical evidence for effect modifica-
tion. In the older age group, current paracetamol use was again found
to be a stronger risk factor for wheeze in affluent countries relative to
non‐affluent countries, though only in the individual level analysis.
In conclusion, these multilevel analyses generally confirm previ-
ously reported child‐level findings for wheeze in ISAAC but, impor-
tantly, they provide additional evidence in favour of direct (rather
than reverse) causation. This is the first comprehensive analysis of
school level associations, which may be particularly relevant to public
health policies, which aim to prevent asthma symptoms by modifying
environment, lifestyle or medication use among whole communities,
rather than individual children or their families.
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APPENDIX
ISAAC PHASE THREE STUDY GROUP
ISAAC Steering Committee: N Aït‐Khaled* (International Union
Against Tuberculosis and Lung Diseases, Paris, France); HR Anderson
(Population Health Research Institute, St George's, University of
London, UK); MI Asher (Department of Paediatrics: Child and Youth
Health, Faculty of Medical and Health Sciences, University of Auck-
land, New Zealand); R Beasley* (Medical Research Institute of New
Zealand, Wellington, New Zealand); B Björkstén* (Institute of Envi-
ronmental Medicine, Karolinska Institutet, Stockholm, Sweden); B
Brunekreef (Institute of Risk Assessment Science, Universiteit
Utrecht, Netherlands); J Crane (Wellington Asthma Research Group,
Wellington School of Medicine, New Zealand); P Ellwood (Depart-
ment of Paediatrics: Child and Youth Health, Faculty of Medical and
Health Sciences, University of Auckland, New Zealand); C Flohr (Unit
for Population‐Based Dermatology Research, St John's Institute of
Dermatology, Guy's and St Thomas’ NHS Foundation Trust and
King's College London, London, UK); S Foliaki* (Centre for Public
Health Research, Massey University, Wellington, New Zealand); F
Forastiere (Department of Epidemiology, Local Health Authority,
Rome, Italy); L García‐Marcos (Pediatric Allergy and Pulmonology
Units, Virgen de la Arrixaca University Children's Hospital, University
of Murcia and Bio‐health Research Institute of Murcia (IMIB), Mur-
cia, Spain); U Keil* (Institut für Epidemiologie und Sozialmedizin,
Universität Münster, Germany); CKW Lai* (Department of Medicine
and Therapeutics, The Chinese University of Hong Kong, SAR China);
J Mallol* (Department of Respiratory Medicine, University of Santi-
ago de Chile, Chile); EA Mitchell (Department of Paediatrics: Child
and Youth Health, Faculty of Medical and Health Sciences, Univer-
sity of Auckland, New Zealand); S Montefort* (Department of Medi-
cine, University of Malta, Malta), J Odhiambo†* (Centre Respiratory
Diseases Research Unit, Kenya Medical Research Institute, Nairobi,
Kenya); N Pearce (Faculty of Epidemiology and Population Health,
London School of Hygiene and Tropical Medicine, London, UK); CF
Robertson (Murdoch Children's Research Institute, Melbourne, Aus-
tralia); AW Stewart (Population Health, Faculty of Medical and
Health Sciences, University of Auckland, New Zealand); D Strachan
(Population Health Research Institute, St George's, University of
London, UK); E von Mutius (Dr von Haunerschen Kinderklinik de
Universität München, Germany); SK Weiland† (Institute of Epidemi-
ology, University of Ulm, Germany); G Weinmayr (Institute of Epi-
demiology and Medical Biometry, University of Ulm, Germany); HC
Williams (Centre of Evidence‐Based Dermatology, University of Not-
tingham, UK); G Wong (Department of Paediatrics, Prince of Wales
Hospital, Hong Kong, SAR China). *Regional Coordinators.
†Deceased.
10 | SILVERWOOD ET AL.
ISAAC International Data Centre: MI Asher, TO Clayton†, P Ellwood,
EA Mitchell, Department of Paediatrics: Child and Youth Health, and
AW Stewart, School of Population Health, Faculty of Medical and
Health Sciences, The University of Auckland, New Zealand.
†Deceased.
ISAAC Principal Investigators: Argentina: Dr CE Baena‐Cagnani*†,
Catholic University of Córdoba (Córdoba), Dr M Gómez, Ayre Foun-
dation; Hospital San Bernardo (Salta); Barbados: Dr ME Howitt*,
Carlton Clinic (Barbados); Belgium: Prof J Weyler, University of
Antwerp (Antwerp); Bolivia: Dra R Pinto‐Vargas*, Caja Petrolera de
Salud (Santa Cruz); Brasil: Prof AJ da Cunha, Federal Universtity of
Rio de Janeiro (Nova Iguaçu), Assoc Prof L de Freitas Souza, Univer-
sidade Federal da Bahia (Feira de Santana, Salvador, Vitória da Con-
quista); Cameroon: Prof C Kuaban*, University of Yaounde
(Yaounde); Canada: Prof A Ferguson, University of British Columbia
(Vancouver), Prof D Rennie, University of Saskatchewan (Saskatoon);
Channel Islands: Dr P Standring, Princess Elizabeth Hospital (Guern-
sey); Chile: Dr P Aguilar, Hospital CRS El Pino (South Santiago), Dr L
Amarales, Regional Hospital “Lautaro Navarro” (Punta Arenas), Dr LA
Benavides, (Calama), Dra A Contreras, Hospital de Castro (Chiloe);
China: Prof Y‐Z Chen*, Training Hospital for Peking University (Bei-
jing, Tong Zhou), Assist Prof O Kunii, University of Tokyo (Tibet), Dr
Q Li Pan, Xinjiang Children's Hospital (Wulumuqi), Prof NS Zhong,
Guangzhou Institute of Respiratory Disease (Guangzhou); Colombia:
Dr G Aristizábal, Instituto de Enfermedades Respiratorias del Niño
S.A. (Bogotá), Dr AM Cepeda, Universidad Metropolitana (Barran-
quilla), Dr GA Ordoñez, Universidad Libre de Cali (Cali); Ecuador: Dr
C Bustos, Hospital Alcivar (Guayaquil); Estonia: Dr M‐A Riikjärv*,
Tallinn Children's Hospital (Tallinn); Ethiopia: Assoc Prof K Melaku,
Addis Ababa University (Addis Ababa); Fiji: Dr R Sa'aga‐Banuve, UNI-
CEF (Suva); Finland: Dr J Pekkanen*, National Public Health Institute
(Kuopio County); Gabon: Dr IE Hypolite*, (Port‐Gentil); Hungary: Dr
Z Novák, University of Szeged (Szeged), Dr G Zsigmond*, Senior
Consultant (Svábhegy); India: Prof S Awasthi, King George's Medical
University (Lucknow), Assoc Prof S Bhave, KEM Hospital Research
Centre (Rasta Peth), Dr NM Hanumante, Ruby Hall Clinic (Pune), Dr
KC Jain, Pioneer Medical Centre (Jodhpur), Dr MK Joshi, Panjat
Hospital (Mumbai (16)), Dr VA Khatav, Dr Khatav's Mother and Child
Hospital (Borivali), Dr SN Mantri, Jaslok Hospital & Research Centre
(Mumbai (29)), Dr AV Pherwani, P.D. Hinduja Hospital and Medical
Research Centre (Mumbai (18)), Prof S Rego, St John`s Medical Col-
lege & Hospital (Bangalore), Prof M Sabir, Maharaja Agrasen Medical
College Agroha (Bikaner), Dr S Salvi, Chest Research Foundation
(Nagpur, Pimpri), Dr G Setty, (Chennai), Prof SK Sharma, All India
Institute of Medical Sciences (New Delhi (7)), Prof V Singh, Asthma
Bhawan (Jaipur), Dr T Sukumaran, PIMS Thiruvalla (Kottayam), Dr PS
Suresh Babu, Bapuji Child Health Institute and Research Centre
(Davangere); Indonesia: Prof Dr CB Kartasasmita, Padjajaran Univer-
sity (Bandung), Prof P Konthen†, Airlangga University (Bali), Dr W
Suprihati, Diponegoro University (Semarang); Iran: Dr MR Masjedi*,
National Research Institute of Tuberculosis and Lung Diseases
(Rasht,Tehran); Isle Of Man: Dr A Steriu, Public Health Specialist,
Information and Research (Isle of Man); Ivory Coast: Dr BN Koffi*,
(Urban Cote d Ivoire); Japan: Dr H Odajima, National Hospital Orga-
nization Fukuoka Hospital (Fukuoka); Kuwait: Dr JA al‐Momen, Al‐
Amiri Hospital (Kuwait); Kyrgyzstan: Dr C Imanalieva*, Kyrgyz Scien-
tific Research Institute of Obstetrics and Pediatrics (Balykchi, Bish-
kek); Lithuania: Assoc Prof J Kudzyte*, Kaunas Medical University
(Kaunas); Malaysia: Prof BS Quah, Melaka‐Manipal Medical College,
(Kota Bharu), Dr KH Teh, Hospital Alor Setar (Alor Setar); Malta:
Prof S Montefort*, University of Malta (Malta); Mexico: Dr M
Baeza‐Bacab*, University Autónoma de Yucatán (Mérida), Dra M
Barragán‐Meijueiro, CoMAAIPE (Ciudad de México (3)), Dra BE Del‐
Río‐Navarro, Hospital Infantil de México (Ciudad de México (1)), Dr
R García‐Almaráz, Hospital Infantil de Tamaulipas (Ciudad Victoria),
Dr SN González‐Díaz, Hospital Universitario (Monterrey), Dr FJ
Linares‐Zapién, Centro De Enfermedades Alergicas Y Asma de
Toluca (Toluca), Dr JV Merida‐Palacio, Centro de Investigacion de
Enfermedades Alergicas y Respiratorias (Mexicali Valley), Dra N
Ramírez‐Chanona, COMPEDIA (Ciudad de México (4)), Dr S Romero‐
Tapia, Hospital de Alta Especialidad del Niño (Villahermosa), Prof I
Romieu, International Agency for Research on Cancer (Cuernavaca);
Morocco: Prof Z Bouayad*, Service des Maladies Respiratoires
(Boulmene, Casablanca, Marrakech); New Zealand: Prof MI Asher*,
University of Auckland (Auckland), Dr R MacKay, Canterbury Health
Laboratories (Nelson), Dr C Moyes, Whakatane Hospital (Bay of
Plenty), Assoc Prof P Pattemore, University of Otago, Christchurch
(Christchurch), Prof N Pearce, London School of Hygiene and Tropi-
cal Medicine (Wellington); Nigeria: Prof BO Onadeko, (Ibadan);
Panamá: Dr G Cukier*, Hospital Materno Infantil Jose Domingo de
Obaldia (David‐Panamá); Peru: Dr P Chiarella*, Universidad Peruana
de Ciencias Aplicadas, UPC (Lima); Philippines: Prof F Cua‐Lim*†,
University of Santo Tomas (Metro Manila); Poland: Assoc Prof A
Brêborowicz, University of Medical Sciences (Poznan), Assoc Prof G
Lis*, Jagiellonian University (Kraków); Portugal: Dra R Câmara, Cen-
tro Hospitilar do Funchal (Funchal), Dr ML Chiera, Hosp. Ped. Coim-
bra (Coimbra), Dr JM Lopes dos Santos, Hospital Pedro Hispano
(Porto), Dr C Nunes, Center of Allergy and Immunology of Algarve
(Portimao), Dr J Rosado Pinto*, Hospital da Luz (Lisbon); Republic
Of Macedonia: Assoc Prof E Vlaski*, University Children's Clinic
(Skopje); Samoa: Ms P Fuimaono V Pisi, (Apia); SAR China: Prof G
Wong, Prince of Wales Hospital (Hong Kong 13‐14); Singapore:
Assoc Prof DY Goh, National University of Singapore (Singapore);
South Africa: Prof HJ Zar*, University of Cape Town (Cape Town);
South Korea: Prof HB Lee*, Hanyang University College of Medicine
(Provincial Korea, Seoul); Spain: Prof A Blanco‐Quirós, Facultad de
Medicina (Valladolid), Dr RM Busquets, Universidad Autonoma de
Barcelona (Barcelona), Dr I Carvajal‐Urueña, Centro de Salud de La
Ería (Asturias), Dr G García‐Hernández, Hospital Universitario 12 de
Octubre (Madrid), Prof L García‐Marcos*, University of Murcia and
IMIB‐Arrxaca Research Institute (Cartagena), Dr C González Díaz,
Universidad del País Vasco UPV /EHU (Bilbao), Dr A López‐Silvarrey
Varela, Fundacion Maria Jose Jove (A Coruña), Prof M Morales‐
Suárez‐Varela, Valencia University‐CIBERESP (Valencia), Prof EG
Pérez‐Yarza, Universidad del Pais Vasco UPV/EHU (San Sebastián);
Sudan: Prof OA Musa, National Ribat University (Khartoum);
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Sultanate Of Oman: Prof O Al‐Rawas*, Sultan Qaboos University
(Al‐Khodh); Syria: Dr S Mohammad*, Tishreen University (Tartous),
Prof Y Mohammad, National Center for Research and Training in
Chronic Respiratory Diseases ‐ Tishreen University (Lattakia), Dr K
Tabbah, Aleppo University Hospital (Aleppo); Taiwan: Dr JL Huang*,
Chang Gung University (Taipei), Dr CC Kao, Kao‐Chun‐Chieh Clinic
(Taoyuan); Thailand: Assoc Prof M Trakultivakorn, Chiang Mai
University (Chiang Mai), Dr P Vichyanond*, Mahidol University
(Bangkok); Tokelau: Dr T Iosefa*, Ministry of Health (Tokelau); Uni-
ted Kingdom: Dr M Burr†, Cardiff University Neuadd Meirionnydd
(Wales), Prof D Strachan, Population Health Research Institute, St
George's, University of London (Surrey/Sussex); Uruguay: Dra D Hol-
gado*, Hospital Pereira Rossell (Montevideo), Dra MC Lapides,
Hospital Paysandú (Paysandú); USA: Dr HH Windom, Asthma and
Allergy Research Center (Sarasota); Venezuela: Dr O Aldrey*, Jefe
del Instituto (Caracas). *National Coordinators. †Deceased.
ISAAC National Coordinators not identified above: Brazil: Prof D Solé,
Universidade Federal de São Paulo; Canada: Prof M Sears, McMaster
University; Chile: Dra V Aguirre, Hospital CRS El Pino; Ecuador: Dr S
Barba, AXXIS‐Medical Centre SEAICA; India: Dr J Shah, Jaslok
Hospital & Research Centre; Indonesia: Prof Dr K Baratawidjaja,
University of Indonesia; Japan: Prof S Nishima, The National Min-
ami‐Fukuoka Chest Hospital; Malaysia: Assoc Prof J de Bruyne,
University of Malaya; Samoa: Dr N Tuuau‐Potoi, Ministry of Health,
Samoa; SAR China: Dr CK Lai, The Chinese University of Hong
Kong; Singapore: Prof BW Lee, National University of Singapore;
Sudan: Dr A El Sony, Epidemiological Laboratory (Epi‐Lab) for Public
Health, Research and Development; United Kingdom, Isle of Man:
Prof R Anderson, Population Health Research Institute, St George's,
University of London.
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